These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 28698350)
1. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol. Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ BMJ Open; 2017 Jul; 7(7):e016914. PubMed ID: 28698350 [TBL] [Abstract][Full Text] [Related]
2. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687 [TBL] [Abstract][Full Text] [Related]
3. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311 [TBL] [Abstract][Full Text] [Related]
4. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial. Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514 [TBL] [Abstract][Full Text] [Related]
5. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial. Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A Drug Res (Stuttg); 2017 Apr; 67(4):244-251. PubMed ID: 28158893 [TBL] [Abstract][Full Text] [Related]
7. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347 [TBL] [Abstract][Full Text] [Related]
8. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Saadati S; Hatami B; Yari Z; Shahrbaf MA; Eghtesad S; Mansour A; Poustchi H; Hedayati M; Aghajanpoor-Pasha M; Sadeghi A; Hekmatdoost A Eur J Clin Nutr; 2019 Mar; 73(3):441-449. PubMed ID: 30610213 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Hadi A; Mohammadi H; Miraghajani M; Ghaedi E Crit Rev Food Sci Nutr; 2019; 59(15):2494-2505. PubMed ID: 29584449 [No Abstract] [Full Text] [Related]
10. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A J Cardiovasc Pharmacol; 2016 Sep; 68(3):223-9. PubMed ID: 27124606 [TBL] [Abstract][Full Text] [Related]
11. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial. Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703 [TBL] [Abstract][Full Text] [Related]
12. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol. Wicklow B; Wittmeier K; T' Jong GW; McGavock J; Robert M; Duhamel T; Dolinsky VW Biochem Cell Biol; 2015 Oct; 93(5):522-30. PubMed ID: 26305052 [TBL] [Abstract][Full Text] [Related]
13. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Mirhafez SR; Farimani AR; Dehhabe M; Bidkhori M; Hariri M; Ghouchani BF; Abdollahi F J Gastrointestin Liver Dis; 2019 Jun; 28():183-189. PubMed ID: 31204416 [TBL] [Abstract][Full Text] [Related]
14. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation. Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703 [TBL] [Abstract][Full Text] [Related]
15. Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease. Çakır M; Aksel İşbilen A; Eyüpoğlu İ; Sağ E; Örem A; Mazlum Şen T; Kaklıkkaya N; Kaya G Turk J Gastroenterol; 2017 Sep; 28(5):377-383. PubMed ID: 28797988 [TBL] [Abstract][Full Text] [Related]
16. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial. Zamani N; Shams M; Nimrouzi M; Zarshenas MM; Abolhasani Foroughi A; Fallahzadeh Abarghooei E; Fattahi MR Complement Ther Med; 2018 Dec; 41():118-123. PubMed ID: 30477827 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Rahmani S; Asgary S; Askari G; Keshvari M; Hatamipour M; Feizi A; Sahebkar A Phytother Res; 2016 Sep; 30(9):1540-8. PubMed ID: 27270872 [TBL] [Abstract][Full Text] [Related]
18. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease. Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901 [TBL] [Abstract][Full Text] [Related]
19. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial. Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283 [TBL] [Abstract][Full Text] [Related]
20. Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease. Pirgon O; Cekmez F; Bilgin H; Eren E; Dundar B Obes Res Clin Pract; 2013; 7(4):e275-83. PubMed ID: 24306155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]